Clinical Updates
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial and Comparative Synthesis
This review synthesizes the BRIGHT-2 trial findings and meta-analytical data, confirming that bireociclib plus fulvestrant significantly improves progression-free survival in HR+/HER2- advanced breast cancer.
